Nymox Pharmaceutical awarded $203,075.40 in Bahamas court order

Nymox Pharmaceutical Corporation reported a final court outcome related to its 2023 litigation.

Accepted by SEC EDGAR 10/22/2025 - 03:38 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nymox Pharmaceutical Corporation reported a final court outcome related to its 2023 litigation. The Supreme Court of the Bahamas issued its final order requiring Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40. This award represents a percentage of expenses previously noted by the Company. The decision provides a defined cash recovery tied to the case and concludes this matter with a court-ordered payment to Nymox.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NYMXF announce in this 6-K?

The Supreme Court of the Bahamas issued a final order requiring certain claimants to pay $203,075.40 to Nymox Pharmaceutical Corporation.

Who is required to pay Nymox the awarded amount?

The order names Mr. Lanham, Mr. Riley, CRNSV, and other claimants.

What is the amount awarded to NYMXF?

The court ordered payment of $203,075.40.

Which court issued the final order?

The Supreme Court of the Bahamas issued the final order.

What does the award represent?

It represents a percentage of expenses from the 2023 litigation previously disclosed by the Company.

Is this decision final?

Yes. The Company stated the court has issued its final order in the matter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October, 2025

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

As reported previously on September 22, 2025, Nymox Pharmaceutical Corporation (the “Company”) was awarded a percentage of expenses from the 2023 litigation brought by Mr. Lanham, Mr. Riley, CRNSV, and others. The Supreme Court of the Bahamas has issued its final order in that matter and has ordered Mr. Lanham, Mr. Riley, CRNSV, and other claimants to pay the Company $203,075.40.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 22, 2025

	NYMOX PHARMACEUTICAL CORPORATION
	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

3